Medication info
Hyundai Pregabalin Tablets 25 mg

Hyundai Pregabalin Tablets 25 mg

Prescription medicationTabletOral
Ingredient · strength
Pregabalin›25mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
White or light yellow round tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201905353 · Approved 2019.07.29 · Insurance code 642004400

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. Creatinine clearance ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended. Adolescent patients aged 12 ~17 years: Use is not recommended.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used in adults to treat peripheral and central neuropathic pain. Additionally, it is utilized as an adjunctive therapy for partial seizures in epilepsy patients, with or without secondary generalized symptoms. It is also effective in treating fibromyalgia. Therefore, it helps improve neuropathic pain and certain types of epilepsy symptoms.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. Creatinine clearance ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended. Adolescent patients aged 12 ~17 years: Use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so patients should immediately inform their doctor if they experience depression or mood changes while taking it. Patients with an allergy to pregabalin or any of its components should not use this medication. Diabetic patients should be cautious as they may need to adjust the dosage of their blood sugar control medications due to weight gain. If symptoms of angioedema occur, such as swelling of the face or around the mouth, the use of this medication should be discontinued immediately and medical advice sought. Elderly patients may experience increased dizziness or drowsiness when taking this medication, so they should take special care when starting treatment and take measures to reduce the risk of falls. Temporary blurred vision or vision changes may occur, and if these symptoms appear, patients should consult their doctor. If this medication is to be used alone after previously using other antiepileptic drugs, it should be used with caution as sufficient data is lacking. Discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, nausea, anxiety, and depression, so dosage should be adjusted according to the doctor's instructions. Patients with a history of substance abuse may have a higher risk of misuse of this medication, so special caution is needed. Patients with impaired kidney function may need dosage adjustments, and improvement in kidney function can help with medication adjustment. Patients with heart disease should use this medication cautiously due to risks such as congestive heart failure. The risk of central nervous system depression increases when used in combination with opioid analgesics, so caution is required if taken together. Patients with weak respiratory function, renal impairment, or elderly patients are at high risk for severe respiratory depression, thus requiring dosage adjustments and careful monitoring. In early pregnancy, this medication can affect the fetus, so women who are pregnant or planning to become pregnant should consult their doctor before taking it and should use effective contraceptive methods. Women who are breastfeeding should consider discontinuing breastfeeding or stopping use of this medication, as it can be transmitted through breast milk. Caution should be exercised when performing hazardous activities such as driving or operating machinery, as dizziness or drowsiness may occur. Rarely, serious skin reactions may occur, and if any unusual symptoms like skin rash or swelling appear, the medication should be stopped immediately and medical advice sought. In case of overdose, symptoms may include confusion, drowsiness, and seizures, and treatment such as dialysis may be necessary.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 180 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual sensation disorder
  • restlessness
  • mood instability
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • lack of inhibition
  • flat affect
  • ataxia
  • motor coordination impairment
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonic jerks
  • diminished reflexes
  • motor disturbances
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremor
  • fainting
  • delirium
  • motor retardation
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • double vision
  • dizziness
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • mood disorders
  • drowsiness
  • confusional state
  • agitation
  • restlessness
  • exacerbation of seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White or light yellow round tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.